FUTURE TREATMENT?
New discovery in Oklahoma could lead to treatment for Tylenol overdose
Acetaminophen, sold over the counter as Tylenol, is one of the world’s most widely used pain relievers. But too much of the drug can lead to serious liver damage.
Now, new research from the Oklahoma Medical Research Foundation has pinpointed the cause of liver bleeding during acetaminophen overdose. OMRF scientists also have discovered a new potential treatment for the condition, which often strikes users of Percocet and Vicodin, pain medications that also contain acetaminophen.
OMRF scientists Courtney Griffin and Siqi Gao discovered that a marked increase in the activity of an enzyme called plasmin caused liver bleeding in the event of acetaminophen overdose.
“It was well known that acetaminophen, like most drugs, is metabolized in the liver. When you get too much of it, toxic byproducts start to build up and can damage liver cells,” said Gao, who is also a Ph.D. student at the University of Oklahoma Health Sciences Center.
“It was also known that a lot of plasmin is generated in acetaminophen overdose, but it wasn’t clear why.”
Griffin and Gao broke new ground by making a connection between plasmin activity and liver bleeding after acetaminophen overdose.
While this finding is important on its own, Griffin said, the OMRF researchers also made a related discovery that yielded important treatment options for overdose patients.
In laboratory mice, the scientists were able to reduce plasmin levels through treatment with tranexamic acid, a prescription medication used to prevent excess blood loss from major trauma or surgeries.
“If the plasmin is breaking down the blood vessels and causing them to rupture, this can help dampen that effect to prevent excessive bleeding,” Griffin said.
In humans, it’s possible that treating this bleeding with tranexamic acid could help facilitate liver recovery from an overdose and also lessen the damage, Griffin said.
“We think it can certainly protect against the bleeding itself, but its role in overall liver recovery is still unknown. That’s the next step for this work.”
The treatment impact of the findings could be significant, Griffin said, especially since tranexamic acid already has been approved by the Food and Drug Administration for another condition.
“It could be administered soon after a patient arrives at the hospital,” she said. “We are excited to see where the next stage takes us.”
The new findings were published in the journal Hepatology. OMRF researchers Florea Lupu and Robert Silasi-Mansat also contributed to the findings. This work was supported by grant No. P30GM114731 from the National Institute of General Medical Sciences, a part of the National Institutes of Health.